Recent Finacing
Recent Raise
Syntimmune is a clinical-stage biotech developing FcRn-targeting therapeutics for IgG-mediated autoimmune diseases, with lead antibody SYNT001 blocking FcRn–IgG in ongoing Phase 1b/2a trials and SYNT002 targeting FcRn–albumin.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors